|
|
 |
 |
| |
 Printable version |
Alemtuzumab in Sézary syndrome: efficient but not innocent |
European Journal of Dermatology. Volume 17, Number 6, 525-9, November-December 2007, Therapy
|
 Free Article
|
Author(s) : Umit Barbaros Ure, Muhlis Cem Ar, Ayse Salihoglu, Sebnem Izmir Guner, Ahmet Baran, Oya Oguz, Burhan Ferhanoglu |
Summary : Mycosis fungoides is the most common form of cutaneous T-cell lymphomas. The related Sézary syndrome is a more aggressive form in which the skin is diffusely affected and the peripheral blood is involved. Although easily managed during its early phases, late-stage mycosis fungoides/Sézary syndrome is usually difficult to treat and becomes refractory to chemotherapy. Recently, promising case-based results have been obtained with alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that binds to CD52 cell surface antigens, in the treatment of advanced stage mycosis fungoides/Sézary syndrome. We report a case of Sézary syndrome treated successfully with alemtuzumab but who died of treatment-related infection. |
Keywords : Alemtuzumab, cytomegalovirus, mycosis fungoides, Sézary syndrome |
|
